Rimonabant reduces obesity‐associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats
暂无分享,去创建一个
P. Soubrié | B. Scatton | F. Oury-Donat | J. Herbert | J. Maffrand | G. Le Fur | M. Gary‐Bobo | G. Elachouri | M. Bensaid | T. Croci | M. Arnone | F. Lacheretz | P. Janiak | C. Roque | J. Gallas | P. Marini | C. Ravinet-Trillou | M. Chabbert | Noël Cruccioli | C. Pfersdorff | Mohammed Bensaid
[1] Y. Aggoun,et al. Obesity, Metabolic Syndrome, and Cardiovascular Disease , 2007, Pediatric Research.
[2] C. Mantzoros,et al. Adiponectin and cancer: a systematic review , 2006, British Journal of Cancer.
[3] F Xavier Pi-Sunyer,et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. , 2006, JAMA.
[4] B. Scatton,et al. The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Cell Proliferation and Increases Markers of Adipocyte Maturation in Cultured Mouse 3T3 F442A Preadipocytes , 2006, Molecular Pharmacology.
[5] Y. Matsuzawa. White adipose tissue and cardiovascular disease. , 2005, Best practice & research. Clinical endocrinology & metabolism.
[6] C. Lavie,et al. Importance and Management of Dyslipidemia in the Metabolic Syndrome , 2005, The American journal of the medical sciences.
[7] J. Després,et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.
[8] T. Hibi,et al. Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice , 2005, Gut.
[9] S. Jee,et al. Obesity, Insulin Resistance and Cancer Risk , 2005, Yonsei medical journal.
[10] F. Poordad,et al. Nonalcoholic fatty liver disease: a review , 2005, Expert opinion on emerging drugs.
[11] U. Pagotto,et al. The endocannabinoid system and the treatment of obesity , 2005, Annals of medicine.
[12] K. Mackie,et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.
[13] T. Kadowaki,et al. Adiponectin and adiponectin receptors. , 2005, Endocrine reviews.
[14] Y. Sharabi,et al. Adiponectin: linking the metabolic syndrome to its cardiovascular consequences , 2005, Expert review of cardiovascular therapy.
[15] A. Rissanen,et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.
[16] N. Chavez-Tapia,et al. Adiponectin as a protective factor in hepatic steatosis. , 2005, World journal of gastroenterology.
[17] R. Pratley,et al. The evolving role of inflammation in obesity and the metabolic syndrome , 2005, Current diabetes reports.
[18] A. Diehl,et al. Cytokines and the pathogenesis of non-alcoholic steatohepatitis , 2005, Gut.
[19] J. Herbert,et al. The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile , 2005, Diabetes, obesity & metabolism.
[20] S. Kihara,et al. Adiponectin as a biomarker of the metabolic syndrome. , 2004, Circulation journal : official journal of the Japanese Circulation Society.
[21] I. S. Wood,et al. Adipokines: inflammation and the pleiotropic role of white adipose tissue , 2004, British Journal of Nutrition.
[22] Cynthia J. Girman,et al. Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.
[23] J. Romijn,et al. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[24] K. Mak,et al. Model of nonalcoholic steatohepatitis. , 2004, The American journal of clinical nutrition.
[25] S. Borst. The role of TNF-α in insulin resistance , 2004 .
[26] G. Marchesini,et al. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[27] G. Sonnenberg,et al. A novel pathway to the manifestations of metabolic syndrome. , 2004, Obesity research.
[28] L. Tartaglia,et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. , 2003, The Journal of clinical investigation.
[29] Cranford L Scott,et al. Diagnosis, prevention, and intervention for the metabolic syndrome. , 2003, The American journal of cardiology.
[30] Yu Wang,et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. , 2003, The Journal of clinical investigation.
[31] P. Soubrié,et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. , 2003, Molecular pharmacology.
[32] P. Soubrié,et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.
[33] S. Kihara,et al. Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice , 2002, Circulation.
[34] S. Maruoka,et al. Decreased plasma adiponectin concentrations in women with dyslipidemia. , 2002, The Journal of clinical endocrinology and metabolism.
[35] J. Beattie,et al. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ , 2001, Proceedings of the Nutrition Society.
[36] R. Palmiter,et al. Leptin-regulated endocannabinoids are involved in maintaining food intake , 2001, Nature.
[37] H. Tilg,et al. Cytokines in alcoholic and nonalcoholic steatohepatitis. , 2000, The New England journal of medicine.
[38] P. Carpino. Patent focus on new anti-obesity agents: September 1999 - February 2000 , 2000 .
[39] G. Gessa,et al. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. , 1998, Life sciences.
[40] P. Soubrié,et al. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats , 1998, Psychopharmacology.
[41] P. Soubrié,et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors , 1997, Psychopharmacology.
[42] B. Spiegelman,et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.
[43] A. Mallat,et al. Endocannabinoids as novel mediators of liver diseases. , 2006, Journal of endocrinological investigation.
[44] L. Sechi,et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. , 2005, European journal of endocrinology.
[45] Manoj Kumar. STONE DISEASE _______________________________________________________________ Obesity, weight gain, and the risk of kidney stones , 2005 .
[46] A. Aljada,et al. Inflammation: the link between insulin resistance, obesity and diabetes. , 2004, Trends in immunology.
[47] M. Haluzík,et al. Adiponectin and its role in the obesity-induced insulin resistance and related complications. , 2004, Physiological research.
[48] S. Borst. The role of TNF-alpha in insulin resistance. , 2004, Endocrine.
[49] B. Goldstein,et al. Adiponectin: A novel adipokine linking adipocytes and vascular function. , 2004, The Journal of clinical endocrinology and metabolism.